Journal Home
Search for

Volume 158, Issue 4, Pages 673-679 (October 2009)


View previous. 31 of 35 View next.

Prevalence and prognostic significance of incidental cardiac troponin T elevation in ambulatory patients with stable coronary artery disease: Data from The Heart and Soul Study

Bill P.C. Hsieh, MDabCorresponding Author Informationemail address, Adam M. Rogers, MDb, Beeya Na, MPHb, Alan H.B. Wuc, Nelson B. Schiller, MD, FACCab, Mary A. Whooley, MDb

Received 9 November 2008; accepted 10 July 2009.

Background

The significance of troponin elevation and clinical utility of troponin testing in ambulatory patients with coronary artery disease (CAD) have not been examined. We sought to investigate the prevalence and prognostic value of cardiac troponin T (cTnT) elevation in a population with stable CAD.

Methods

We studied 987 patients with stable CAD enrolled in the Heart & Soul study who had plasma cTnT measurements before performing exercise treadmill testing.

Results

Of the studied population, 58 patients or 6.2% had detectable cTnT levels, ≥0.01 ng/mL (0.01-0.72 ng/mL). During a mean follow-up period of 4.3 (0.1-6.5) years, 58.6% of participants with detectable cTnT had cardiovascular events compared with 22.5% of those without detectable cTnT (hazard ratio [HR] 3.8, 95% CI 2.6-5.4, P < .001). This association remained strong after adjustment for traditional risk factors and C-reactive protein (HR 2.0, 95% CI 1.3-3.1, P = .002). However, after further adjustment for N-terminal pro–B-type natriuretic peptide and echocardiographic parameters of left ventricular function, cTnT elevation was not an independent predictor of cardiovascular events (HR 1.3, 95% CI, 0.8-2.3, P = .28).

Conclusions

In ambulatory patients with stable CAD, the prevalence of cTnT elevation was 6.2%. Cardiac troponin T elevation detected using the conventional troponin assay was associated with increased risk of adverse cardiovascular outcomes, but its prognostic value was not incremental over N-terminal pro–B-type natriuretic peptide and echocardiographic evidence of cardiac abnormalities.

a Division of Cardiology, Department of Medicine, University of California, San Francisco, San Francisco, CA

b Veterans Affairs Medical Center and Department of Medicine, University of California, San Francisco, San Francisco, CA

c Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA

Corresponding Author InformationReprint requests: Bill P. C. Hsieh, MD, Heart and Soul Study, 4150 Clement St (111A1), San Francisco, CA 94121.

PII: S0002-8703(09)00548-1

doi:10.1016/j.ahj.2009.07.021


View previous. 31 of 35 View next.